All times displayed for Europe/Berlin timezone.

BioProduction - Free to attend content

Bioproduction Keynote Presentations: Bioproduction Plenary Stage - 120A02
09:50 - 10:50 120F38
BioProduction Theatre

• 09:50 - 10:20 Keynote Presentation: Next generation bioprocessing technologies, facility design and products to improve process productivity and increase capacity
• 10:20 - 10:50 Keynote Presentation: Delivering high-quality therapeutics to patients faster through effective data management

• Daniela Ottini, VP, Manufacturing Operations Biologics, Abbvie, Ireland
• Unjulie Bhanot, Solution Owner (Biologics Development), IDBS, UK

Market Outlook: Global trends and growth opportunities in the biopharmaceutical product development and manufacturing
11:50 - 12:20 120F38
BioProduction Theatre

Speaker: Eric Langer, Managing Partner, BioPlan Associates, Inc. USA

Market Outlook: Opportunities and the evolving biopharma landscape in asia-pacific
12:30 - 13:00 120F38
BioProduction Theatre

Speaker: Eric Langer, Managing Partner, BioPlan Associates, Inc. USA

Live Labs: Join the Live Labs tour to gain an insight into some of the most innovative equipment and services to hit todays biopharmaceutical market
13:15 - 14:10 120F38
BioProduction Theatre

• 13:20 Live Lab Tour Presentation 1: GE Healthcare
• 13:30 Live Lab Tour Presentation 2: Gyros Protein Technologies
• 13:40 Live Lab Tour Presentation 3: Hamilton
• 13:50 Live Lab Tour Presentation 4: Saint Gobain
• 14:00 Live Lab Tour Presentation 5: Pall Biotech

Spotlight Presentation: Available Slot
14:30 - 15:00 120F38
BioProduction Theatre

Please contact [email protected] for further details.

Panel Discussion: Risk Mitigation and Ensuring Single Use Supply Chain Security
15:10 - 15:40 120F38
BioProduction Theatre

• Bruno Tricoire - Head of Tech Transfers and leader of the Sanofi Single Use Network
• Sanofi Pasteur, France

Pharma Insight Briefings

Global Outlook: The Future of Biosimilars
10:30 - 11:40 61D61
CPhI Theatre
Senior Consultant
Vice President & General Manager
Samsung Bioepis
Executive Editor at Generics bulletin
Informa Pharma Insights
Managing Director
Global Head of Commercial
Sandoz Biopharmaceuticals

Biosimilars are an indispensable tool for providing patient access to innovative, effective therapies whilst keeping healthcare costs sustainable. This panel will assess the global outlook: Europe’s reasonably mature market, new Asian players and the challenges to adoption in the US.
• Creating a sustainable market in Europe
• How can the US adopt biosimilars?
• Future commercial opportunities
• Strength of Asian players
• How do biosimilars affect non-reference therapies?
• Incentivizing innovation
• Humira – one year on the market

Understanding the Cell & Gene Technology Opportunity
10:30 - 11:40 120G43
ICSE Theatre
Head of Strategic Marketing & Market Insights for Cell and Gene Therapies
Associate Editor
PharmSource – a GlobalData Product
Senior Manager
Vice President, Business Development – Manufacturing
Oxford BioMedica
Vice President – Market Access
ALira Health
VP and GM of Viral Vector Services
Thermo Fisher Scientific
Head of Gene Editing and Novel Modalities
Chief Technology & Strategy Officer
Paragon Bioservices

Cell and Gene therapies provide treatment solutions to patients with previously unmet needs, and with regulators poised ready for an influx of product approvals in the coming years, the sector offers a significant commercial opportunity. This panel will discuss the investment opportunity for those looking to enter this ever-evolving sector.
• Sector outlook and long-term opportunities
• What is the right investment now for CDMOs?
• Creating the right infrastructure to support innovation
• Commercialisation & pricing challenges
• Logistics & supply dynamics

Improving Patient-compliance and adherence through Packaging/Device innovations
10:30 - 11:40 110D50
InnoPack & P-MEC Theatre
VP of Regulatory Affairs
Vice President Marketing Pharma Division
Constantia Flexibles
Managing Director & Executive Director
NVC Packaging Centre & HCPC Europe
Director Front End Innovation

Sponsored by:

[In collaboration with Pharmapack Europe]
Many patients still fail to take their medicines as instructed, meaning adherence continues to be a key challenge for the Pharma Packaging industry. This panel will look at the latest innovations geared towards improving health outcomes through patient adherence and compliance.

“Ceutical” Renaissance in Isolated Derivatives and Extracts of Cannabis
11:50 - 12:20 61D61
CPhI Theatre
KGK Science

Sponsored by:

With recent regulatory changes tostate and national laws, cannabis is undergoing a period of rediscoveryandattraction from industries. Hemp was a vital crop and form of currency in the American colonies, but tobacco and cotton pushed hemp to the side as a major cash crop by the late 1800s. The re-evaluation of U.S. and Canadian medical marijuana laws over the past decade has driven novel innovation in food products with hemp-derived cannabinoidssuch as cannabidiol (CBD). Chronic CBD users represent 7% of the American population,and North American use rates areexpected to rise as access to hemp-derived CBD food products increases.In preclinical studies, CBD shows potential therapeutic efficacy against a diverse assortment of medical conditions including seizure disorder, psychosis, anxiety, depression, inflammation, cancer, cardiovascular disease, neurodegeneration, multiple sclerosis and chronic pain. Other than rare seizures, there are clinical trial research gaps in CBD use for mostmedical conditions. Investment to substantiate structure-function claims (occasional pain, sleeplessness, anxiety, and inflammation) is also lacking. Time will tell whether this CBD renaissance is met with scientific rigor

Analytical Development and Technico-Regulatory expertise all along the pharmaceutical development and manufacturing
11:50 - 12:20 120G43
ICSE Theatre
Analytical Development Manager

Sponsored by:

Skyepharma is a CDMO specialized in controlled release and other complex drug formulation.In support to development and manufacturing, analytical development and regulatory teams are involved at the beginning of the project since the quotation. Case studies from Skyepharma portfolio will be presented and discussed. They will illustrate our agility to be operational as
soon as the project begins using the expertise of support teams

Visualizing the cell and gene therapy supply chain of the future
11:50 - 12:20 110D50
InnoPack & P-MEC Theatre
Vice-President, Global Pharmaceutical

Sponsored by:

Today’s healthcare and pharmaceutical supply chains are ineffective and inefficient due to a lack of visibility and transparency and are in dire need of a technology upgrade. Recent breakthroughs in biotechnology and more recently the cell and gene therapy arenas have yielded miracle cures,and morethan 900 additional potential therapies are currently in the research and development pipeline; however, the waysof delivering such therapiesare stuck in the 1980s, for the most part. Supply chain issues are still relatively complex when it comes to manufacturing CAR-T therapies, resulting inincreased logistical costsand high risk of human error at every step of the delivery process. If treatment providers are to gaina competitive advantage, they will need to adopt new technology-based approaches, such as implementing a software platform that connects all of the partners inthe supply chain to meet the needs of all stakeholders, from healthcare providers to patients, quickly and reliably. This presentation will proposean innovative, scalable software platform that integrates seamlesslywith existing andfuture information technology systems, providing unprecedented visibility and transparency all along the supply chain, right up to the patient.

Telemedicine and the opportunities for rethinking drug product development
12:30 - 13:00 61D61
CPhI Theatre
Graz University of Technology

Sponsored by:

Telemedicine has already been suggested 15 years ago to revolutionize the drug therapy to patients but it is only recently that clinical evidence is coming through. With providing benefits to patients, the implementation of telemedicine will move very fast, putting increasing pressure on the pharmaceutical industry to provide more tailored and patient centric drug products to the market. This presentation will summarize the actual status of telemedicine and provides some case studies on how to leverage existing formulation and manufacturing technologies to provide individualized medicines to patients.

Shifting from Productivity toInnovation: How the RightOutsourcing Partner Can Catalyze Your Integrated Drug Development Initiative
12:30 - 13:00 120G43
ICSE Theatre
Chief Operating Officer
Syngene International

Sponsored by:

Biotech market trends enhancing new requirements for PFS sealing solutions: BD™ Premium Coat 1mL Plunger Stopper offering for biologics
12:30 - 13:00 110D50
InnoPack & P-MEC Theatre
Global Strategic Marketing PFS
Becton Dickinson & Co

Sponsored by:

Biotech market for chronic disease application is evolving at a high pace. Market dynamics are creating new challenges for pharma enhancing new requirements for drug delivery solutions. Developing and providing pharma companies with high quality integrated and continuously improving combination product solutions as well as supporting our customers through the effort of biologic drug development is BDM-PS mission. With the rise of evolving challenges around biologic drug viscosity, volume and advanced formulations, requirements to raise the bar in terms of injection system functionality and predictability become a 'must have'. The new PFS sealing solution - Premium Coat 1mL Plunger Stopper offering for biologics - is one example of how BDM-PS holds the challenge of providing pharmaceutical companies with the system performance and predictability expected for tomorrow's injectable biologics.

How Silica (gel) has enabled Pharma and Nutraceutical Manufacturing to Overcome Regulatory and Developmental Challenges
13:10 - 13:40 61D61
CPhI Theatre
Global Marketing Leader
W. R. Grace & Co

Sponsored by:

The pharma IP and regulatory environment is in a constant state of flux. These changes have forced the pharma sectorto innovate and or reformulate their products not only to comply with regulations or to differentiate their products but also to manage cost. From continuous manufacturing to Mesoporous Therapeutic Delivery, amorphous silica gel has been successfully usedto overcome several formulation challenges. By means of some representative case studies this talk outlines where key challenges commonly faced in the pharma and nutraceutical sector were overcome through the incorporation of mesoporous silica gel into the formulation.

The latest trends of the CDMO small molecules APIs
13:10 - 13:40 120G43
ICSE Theatre
Senior Vice President Business Development

Sponsored by:

Advitech Advisory and Technologies sa, a Swiss advisory firm focused on healthcare and fine chemical industry, within its business intelligence activities, is now focusing on a new project APIsTRENDS: collection of Reports on the active pharmaceutical ingredients (APIs) world.
The Advitech Reports offer an original contribution to the APIs business community, comprising APIs producers, clients and investors/shareholders providing an information tool, based on the analysis of companies operating in this important sector.
The last efforts of APIs TRENDS collection are concentrated on the global contract development and manufacturing organization (CDMO) market which is experiencing a constant growth and increasing interest in the healthcare world.
The CDMO rise is a key aspect of the pharmaceutical industry’s evolution, where two-thirds of pharmaceutical manufacturing is outsourced and Advitech has identified the major trends impacting this sector, with a specific focus on small molecules.
Advitech has now combined the previous CDMO Benchmarking Report - Baseline Analysis with the latest data and we are able to outline a three-year trend update, CDMO Benchmarking Report 2017-2018, an unprecedented approach in this industrial sector.

The Use of DPTE® Rapid Transfer Technology to ensure sterility and prevent contamination within Barrier Systems
13:10 - 13:40 110D50
InnoPack & P-MEC Theatre
Product Manager Sterile Transfer Solutions

Sponsored by:

Microbial contamination from operators is the greatest danger to sterile medicinal products in pharmaceutical manufacturing. Another is the incorporation of particles in the aseptic process. The DPTE® ultra-clean patented transfer system provides barrier solutions to both these issues. This is how thevalidatedcombination ofAlpha ports and pre-filled ready-to-use DTPE-BetaBags® leads to higher productivity and high-quality production.

Quality by Design and Continuous Improvement as a basis for high product quality
13:50 - 14:20 61D61
CPhI Theatre
Senior Director Quality
Capsugel - Lonza

Sponsored by:

Why inhalation is the drug delivery technique to watch
13:50 - 14:20 120G43
ICSE Theatre
Global Key Account Director for Inhalation

Sponsored by:

Inhalable drug products offer several advantages when it comes to ensuring targeted drug delivery. However, they also present several challenges during development and manufacturing, requiring experience and technical capability. While drug companies often have in-house expertise for drug discovery, early development and small-scale production, few can manufacture inhalation drugs for clinical trials and –assuming they win approval –commercial supply. In this briefing, Recipharmreviews the key advantages and challenges associated with inhalation drug development and explores techniques to reduce time to market. In summary, the session will cover:-Challenges and key considerations during inhalation drug development-Navigating scale-up and tech transfer-Reducing time to market -Regulatory considerations (including the 505(b)(2) pathway)-An overview of Recipharm Inhalation Solutions™

Driving Foreign Particulate Analysis: How to Choose Between Manual and Automated
13:50 - 14:20 110D50
InnoPack & P-MEC Theatre
Gateway Analytical, an Aptar Pharma Company

Sponsored by:

Foreign particulate analysis is a critical aspect of pharmaceutical manufacturing and non-conformance investigations. The approaches and methodologies for analyzing foreign particulates vary depending on single particle investigations or population studies. During this presentation, a brief overview of manual and automated techniques used for foreign particulate matter (FPM) investigations will be presented. A variety of different case studies utilizing manual or automated techniques to determine identification of FPM and forensic approaches to source determination will be discussed. This presentation will also highlight how rapid turn-around identification techniques can quickly provide answers during investigations.

Managing the natural variability of plant-based pharmaceutical ingredients (example of Vegetable oils)
14:30 - 15:00 61D61
CPhI Theatre

Sponsored by:

Why managing variability?Pharmaceutical ingredients play a key role in drug formulation.Variations in their composition and physicochemical properties can have significant impact on the final drug product performances like safety, physical and chemical stability and bioavailability. In the recent past, ingredient variability has been at the origin of FDA recalls.Natural-based products are by definition subject to a certain degree of variability but appropriate solutions can be developed to manage this variability and propose consistent plant-based pharmaceutical ingredients. As a manufacturer of highly purified vegetable oils, SIO has implemented a full management of this natural variability.Risk assessment can be used to understand variability of naturally-derived pharmaceutical ingredients and identify which material attributes have an impact on the performances of the final dosage form.

Applying innovative thinking to analytical services: Techniques to reduce time to market
14:30 - 15:00 120G43
ICSE Theatre
Director, Analytical Development

Sponsored by:

Analytical methods are crucial for the development of any pharmaceutical drug product, be it generic or new drugs. Applying new, innovative techniques and modern instruments can significantly reduce time to market, helping to bring new drug products to patients faster. Advanced instrumentation plays a significant role in not only estimating “what is expected” of the drug product, but also what is not expected. That said, producing quality products is only possible with a forward-thinking mindset and keen attention to these technological advances. In this briefing, Recipharm provides case study examples of where improvements to method development and validation have resulted in significant time savings. Dr. Ramesh Jagadeesanalso explores the need for effective problem solving during analytical chemistry and why expertise in drug development and commercial manufacturing can help to improve efficiencies. In summary, the session will cover:-The importance of innovation during analytical chemistry-How time to market can be reduced during the analytical testing stage-Case study examples of improved method development and validation-Why knowledge of the entire drug development and manufacturing process is of value during analytical testing.

Advantages of Nasal Powders for Drug Repurposing
14:30 - 15:00 110D50
InnoPack & P-MEC Theatre
Director, Scientific Affairs
Aptar Pharma

Sponsored by:

Although nasal spray drug products have been around for a number of years, recent developments have brought renewed interest to this market. The scientific and medical advantages of drug delivery using nasal sprays are well documented and include a non-invasive approach removing any associated pain or anxiety related to injection, rapid onset of action, good bioavailability compared to oral administration and high levels of acceptability resulting in improved comfort and compliance for patients. As compared to oral forms of treatments, intranasal delivery also benefits from the avoidance of first pass metabolism.

With healthcare costs rising globally there is a growing demand for therapeutically relevant medications that can be developed quickly and at reasonable costs for a variety of diseases and also for high unmet medical needs. Nasal drug delivery continues to offer significant opportunities for repurposing drugs. This talk will look at some of the advantages and challenges of developing some of these drug repurposing candidates as nasal powders.

Lonza Engine™ equipment portfolio for small molecule bioavailability enhancement, particle engineering and drug product development
15:10 - 15:40 61D61
CPhI Theatre
Technical Service Engineer
Capsugel - Lonza

Sponsored by:

Fill & Finish of live vaccines – a CDMO perspective
15:10 - 15:40 120G43
ICSE Theatre
Sr. Director - Head of Sales
Bavarian Nordic

Sponsored by:

The fill&finish operations for viral vaccines require some specific attributes to facility and equipment. In this presentation Bavarian Nordic will guide you through the design, construction and qualification of their new fill&finish facility at their headquartersin Denmark.This facility will allow for filling and lyophilization of live vaccines in a BSL2 environment and will have dedicated capacity for CDMO services

Beyond Pharmaceutical Packaging: New Solutions to Old Challenges
15:10 - 15:40 110D50
InnoPack & P-MEC Theatre
Vice President, Commercial Operations
Aptar CSP Technologies

Sponsored by:

Tablets and capsules are today’s most popular drug delivery forms. However, in their development, there are many challenges overcoming moisture, oxygen and reactive impurities. These challenges are likely to increase with the development of more potent API’s, larger molecules and modified release profiles
As traditional packaging options can be ineffective and/or inefficient, there is a need for new and specialized active packaging solutions. Additionally, repetitive design processes and reformulations, from stability failures, are costly and can delay product launches.
This presentation will look at the sources of moisture and oxygen in oral solid dose (OSD) blister packaging and common approaches to mitigate. Active desiccant and scavenger management technology (Activ-Blister™ Solutions), can meet these challenges and expedite time-to-market.

The 3 phase active polymer platform technology provides integrated solutions applicable for oral solid dose,Dry Powder Inhalers, pMDIs, and Transdermal drug products. The platform technology improves stability, shelf-life extension, and secures speed to market. They are also suitable for marketed products seeking to extend shelf life and/or optimize packaging.

Building Oligonucleotide Manufacturing Capabilities within an Established Peptide CMO
15:50 - 16:20 61D61
CPhI Theatre
PhD, Business Development Manager

Sponsored by:

Bachem’s specialty as a successful Contract Manufacturing Organization is the controlled manufacture of high-value, pharmaceutical-grade peptides using chemical synthesis technologies. Bachem now is strategically diversifying its technology platform to include the manufacture of synthetically accessible RNA and DNA molecules (oligonucleotides). This presentationdescribes the building up of oligonucleotide capabilities while exploiting manufacturing technology, analytical know-how, and regulatory compliance synergies with peptides. The presentation will also point out processing differences between the two drug classes and learnings to be undertaken on the way to the first “Tides CMO” offering large-scale manufacturing services for both, peptides and oligonucleotides.

Navigating the Solid Form Landscape during API Development
15:50 - 16:20 120G43
ICSE Theatre
Executive Director, Technical Services

Sponsored by:

During development, understanding the polymorphic landscape of an active pharmaceutical ingredient (API) is of utmost importance to ensure that the most suitable solid form is reproducibly prepared and no batch-to-batch variability resulting in inconsistent solubility, dissolution rates, stability, crystallinity or particle properties is encountered. Water plays a key part in development due to its presence in the atmosphere, drug product excipients, and exposure during different routes of administration.Understanding the effect of water on the polymorphism of an API is critical in development. Within a product, water can prompt dissolution of soluble components, increase interactions between API and excipients, or induce API-specific phase transitions. Due to these risks, the impact of water should be fully understood in all aspects of drug development and manufacturing. Cambrex Edinburgh will present methods to locate, understand and map out the crystallisation space of hydrated forms and describe the impact they have on downstream processing.

Container Closure Integrity Testing of Sterile Pharmaceutical Product Throughout the Product Life Cycle
15:50 - 16:20 110D50
InnoPack & P-MEC Theatre
Director Product Line
Lighthouse Instruments

Sponsored by:

Container closure integrity (CCI) plays an important role in maintaining the sterility and stability of sterile injectable products. Defects which cause a sterile vial to leak are not necessarily defects that will be detected by a visual inspection process. Examples of such defects are microscopic cracks & scratches in the glass, defects hidden by the crimp, or temporary defects such as stopper pop-up that result in temporary container leakage.  New regulatory guidance is driving changes to industry best practices for CCI testing (CCIT).  Traditional CCIT methods such as microbial challenge or blue dye ingress tests are described as methods associated with probabilistic outcomes which lead to difficulties in quantitatively validating the test method for the detection of critical leaks.  The new regulatory guidance also makes clear that container closure integrity testing should be performed throughout the product life cycle.  Deterministic CCIT methods based on non-destructive analytical measurements coupled with a risk-based approach can be used to generate statistical CCI data enabling informed decisions about implementing a container closure integrity inspection process in commercial manufacturing.  This presentation summarizes the current state of container closure integrity testing in the industry and outlines a framework for developing a holistic CCIT strategy.

How to export medicine to China? Updates on pharma regulations and “4+7” procurement policies
16:30 - 17:00 61D61
CPhI Theatre
Consultant of Regulatory Affairs
Accestra Consulting Company

Sponsored by:

After China joined ICH, China begins to close the drug development gap and has significantly reformed its drug regulatory system and introduced a whole new pharmaceutical procurement policy called “4+7” in piloting cities. This industrial systematic reformopened large opportunities for overseas pharmaceutical companies. On one side, the “4+7” policy gives transparent and open competition environment towards both local and overseas pharma producers, moreover, along with the 4+7 procurement policy, Chinese government launched “accelerated approval” drug registration review system with the purpose of encouraging innovation and reducing regulatory burden to attract more medicines with high quality and urgent clinically needs to the Chinese market. Companies that follow Chinese government’s orientation can make use of the concessions under the reforms and enjoy the reduced R&D cost and faster enter to the second-largest market in the world. In this seminar, you will find the interpretation of China’s current pharmaceutical regulation and the newly published “4+7” rules. Besides, regulatory compliance suggestions will be provided to the overseas companies who are interested in the opportunities of this attractive market.

Assessing the compatibility of Drug/device combination products – finding a perfect match
16:30 - 17:00 120G43
ICSE Theatre
PhD, Department Head Micro and Pharma
Nelson Labs

Sponsored by:

The increasing use of and interest in innovative combination products –products combining a drug anddevice,–is raising significant challenges both for regulators and the industries they regulate.Using specific case studies, this talk will present the challenges that Nelson Labs Europe has overcome in drug-device compatiblitystudies of drug/device products from a practical, analytical and regulatory point of view.

Ready-to-use packaging solutions to transform injectable drug manufacturing
16:30 - 17:00 110D50
InnoPack & P-MEC Theatre
Director Business Development Sterile Solutions
SCHOTT Pharmaceutical Systems
Senior Global Product Manager

Sponsored by:

The global Pharma industry is changing with the advent of specialized biotech drugs, personalized medicine and cell and gene therapies. Injectable drug manufacturing must become more efficient, flexible and less complex. These objectives can be met by shifting from bulk to ready-to-use (RTU) containers/systems (vials, cartridges, PFS). Creating a universal standard for all RTU containers will offer highest flexibility and reduce the risk for Pharma companies and to patients. We will share insights on how RTU solutions like SCHOTT’s iQ™ platform will accelerate and ease drug development, manufacturing and delivery of complex biotech drugs. We will also highlight the use of “big data” analytics in injectable drug manufacturing.


Global Regulatory Outlook and Regional Trends
11:00 - 12:00 80B10
World of Pharma Podium
Ph.D, Head of Regulatory and Pharmacovigilance Solutions
Clarivate Analytics

Increased R&D productivity in biotech and pharma means more drugs are being evaluated by health authorities and launched in world markets, with 2018 seeing the highest ever number of FDA new drug approvals. Shifting priorities in global pharma pipelines to rare diseases and advances in drug technologies means regulators are evolving guidelines to evaluate more drugs with less data to find meaningful, cost-effective therapies for patients in need. To understand the current landscape, this presentation will examine global and regional trends in:
• Global harmonization and convergence
• Patient engagement and real-world data
• Bridging the gap between HTA and regulatory
• Next-generation biologics manufacturing
• Generics and biosimilars

Panel discussion: Exploring the Medicinal Cannabis Opportunity for Pharma
11:00 - 12:00 41K01
Natural Extracts Podium
EVP Scientific Affairs
Avicanna Inc.
Cannabis Researcher and Consultant
Director, Global , Offering Management, Consumer Health
Senior Principal
Axon Life Sciences Lawyers
Technical Director
Lonza Pharma Biotech & Nutrition
Professor of Psychiatry
Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School

• Current state of play and scale of the opportunity
• Potential benefits across therapeutic areas
• Europe Vs the US market
• Regulatory uncertainty and challenges
• The Clinician’s View

Opportunities and Challenges of Chinese Pharmaceutical Market
12:00 - 12:45 80B10
World of Pharma Podium
General Manager, International Business
3S Pharmaceutical Group
Natural Extracts Supply Chain
12:15 - 13:15 41K01
Natural Extracts Podium
Chief Executive Officer

Sponsored by:

This presentation will provide the audience with an overview of the key elements that effect the supply chain in regards to natural extracts. It will also explain, why those elements are important and best practices that are being introduced in this area.

- How do we really define “supply chain” and why is it important
- The role of the contract manufacturer
- Integrity of the supply chain
- The importance of quality and how auditing fits in
- Best practices to insure your supply chain is helping and not hindering your organizations success

The Impact of the Indian Pharma Industry on global health
12:45 - 13:30 80B10
World of Pharma Podium
Head of API & Customer Pharmaceutical Services
Dr Reddy's
Lunch Break
13:30 - 14:00 80B10
World of Pharma Podium
Exploring the Mental Health & Wellness Trend in Natural Extracts
13:30 - 14:30 41K01
Natural Extracts Podium
Head of Research and Development
Anklam Extrakt
Founder, Herbal Pharmacist
Anklam Extrakt
Vice President Content – Health & Nutrition
Informa Markets

• Increased interest from a younger demographic in joint & cognitive health
• Treating anxiety and depression with natural extracts

Market Trends of Korean Biopharmaceuticals
14:00 - 14:45 80B10
World of Pharma Podium
Policy & Regulatory Affairs Team Manager
Thyme & Primula – the natural combination solution for cough relief
14:30 - 15:00 41K01
Natural Extracts Podium
Research Manager
Anklam Extrakt

Sponsored by:

Finding Opportunities in Southeast Asia
14:45 - 15:15 80B10
World of Pharma Podium
Senior Consultant

Sponsored by:

  • Southeast Asia and its place in global pharma
  • Key insights and growth drivers in the region
  • Future opportunities and challenges
The new ingredient for prostate food supplements
15:00 - 15:30 41K01
Natural Extracts Podium
Assistant Scientific Director
EPO Estratti Piante Officinali Srl

Sponsored by:

ENOTprost is the new ingredient for prostate food supplements: it is the first dry extract of Epilobium angustifolium L. standardized to contain 15% Oenothein B. ENOTprost, thanks to the rich phytocomplex, has been proved to have prostate-specific activity reducing inflammation and oxidative stress, which are important risk factors for prostatic disease development and cronicity. Prostatic ailments and in particular BPH (benign prostatic hyperplasia) are among the most common urologic problems in men aged 50 and over, although prostatitis can also affect young people, especially sportsmen and cyclists. Let prostate problems fly away with ENOTprost, the right ingredient for male wellness!

M&A Forum

Presentation: Deals, Deal Deals: Analysis of 2019 and Outlook for 2020
15:30 - 16:00 World of Pharma Podium, 80B10, Frankfurt Messe
M&A Forum
Principal Analyst
Pharma Intelligence

Sponsored by:

Speaker: Representative, Informa Market Intelligence

It's free to attend, but seats are limited – please register your interest HERE!

Where do mega-mergers leave smaller players, what will be the role of the entrepreneurs driving innovation, and what are the more practical implications for companies going through the expensive and disruptive merger process?
15:30 - 17:30 World of Pharma Podium, 80B10, Frankfurt Messe
M&A Forum

Sponsored by:

2019 kicked off with USD$92 billion* worth of high-profile acquisitions in the United States alone, including Bristol Myers Squibb’s purchase of Celgene, and Eli Lilly’s takeover of Loxo Oncology. An impressive start to the year, but will this continue at pace throughout 2019 and what’s the outlook for 2020?
As Pharma companies turn more to acquisitions to acquire new technologies, boost pipelines and increase capabilities, we ask what the fallout of a shrinking market may be. Where do mega-mergers leave smaller players, what will be the role of the entrepreneurs driving innovation, and what are the more practical implications for companies going through the expensive and disruptive merger process?

This roundtable will address the current M&A landscape, analyse deal drivers in-depth, and examine the potential implications of so much consolidation. This free to attend event will give you the opportunity to hear from dealmakers, investors and innovators on the current outlook, and will provide an important opportunity for networking at CPhI Worldwide.

*Source: Informa Pharma Intelligence

It's free to attend, but seats are limited – please register your interest HERE!

Panel discussion: Assessing the M&A Landscape for Pharma
16:00 - 17:30 World of Pharma Podium, 80B10, Frankfurt Messe
M&A Forum
Results Healthcare
Group Vice President, Strategy
Thermo Fisher Scientific
Informa Pharma Consulting
VP, Head of Business Development
Executive Partner & Founder
GHO Capital
Executive Vice President Corporate Development
Recipharm AB

Sponsored by:

•Key factors driving deal activity, will this continue at pace?
•Assessing the targets: chronic disease, HPAPI, cell and gene therapies, biologics
•A changing market: what are the implications of vertical integration and consolidation, where does this leave SMEs?
•Impact on innovation & R&D, what’s the role of the entrepreneur amidst so much consolidation?
•Internal dynamics: What’s the fallout of M&A on staff and senior leadership?

It's free to attend, but seats are limited – please register your interest HERE!

Women in Leadership Forum

How to Build A Future Fit Workforce: How do we create an environment where everyone has the opportunity to fulfil their full potential?
15:30 - 18:30 Frankfurt Marriott hotel (opposite CPhI main entrance site)
Women in Leadership Forum
Global Sourcing Manager
Boehringer Ingelheim
Member of Diversity & Inclusion Council
Director in Vaccines Network and Supply Chain Design
Merck Sharp & Dohme Corp
Senior Manager of Communications
Executive Coach & Client Development
The Executive Coaching Consultancy
International Customer Analytics Director
Eli Lilly
Founder & Board President
greenlight for girls
Head of HSE Management Systems
Global Diversity & Inclusion Consultant

Sponsored by:

For the sixth year running the Women in Leadership Forum will take place on the second day of CPhI, this year moving to a new off-site location. Situated directly opposite the main entrance to the Frankfurt Messe on Hamburger Allee, this year’s forum will take place at the Frankfurt Marriott hotel for an afternoon session, closing with a cocktail reception and networking.

This year’s discussions will focus on how we build a ‘future-fit’ workplace, reviewing the challenges with current dynamics and asking how to create an environment where everybody can achieve their full potential.

All Welcome! Don’t let the name deter you! Men are always welcome to attend the Women in Leadership Forum, in fact, we encourage it! To change the status quo, more men need to understand the issues faced by female peers and actively stand-up and speak-up for them. Take the first step toward becoming an important ally to your female colleagues and help build the foundations for the future workplace.

Why Attend?
• Meet your peers away from the show floor- the 2018 edition was attended by senior representatives from Pfizer, Dr. Reddy's Laboratories, Merck, ISPE, Catalent, Sanofi and more.
• Hear from inspirational speakers on strategies for building and improving diversity in pharma, and takeaway solutions for kick-starting change in your own organisation.
• Network with like-minded professionals from across the global pharma network and share your own goals and experiences.

15:30 | Welcome from Dupont
Angela Strzelecki, Business Director - Pharma Solutions, DuPont Nutrition & Biosciences
Amina Faham, Global Pharma Application Leader, DuPont Nutrition & Biosciences
Rina Chokshi, Global Field Marketing Leader - Pharma Solutions, DuPont Nutrition & Biosciences

15:40 | Making Diversity & Inclusion a reality in the workplace
Interview with Antonio Bebba, Member of Diversity & Inclusion Lead and Ulrike Großheim, Senior Manager of Communications at Pfizer

16:00 | Inspiring the future female workforce
Melissa Rancourt, Founder & Board President, Greenlight for Girls

16:10 | Dynamic Networking:

Participants will work together to discuss key topics and challenges facing us in the workplace.

Each table will be moderated by an expert in the area and participants will join two discussions:
• Maternity/paternity training for employers - Helen Ilsley, Executive Coaching
• The Agile way of working: experience and learning at a German corporation - Daila Acanfora, Boehringer Ingelheim
• How to be boardroom ready - Birgit Skuballa, Bayer
• Importance of Intersectional leadership – Kathy Teoh, DSM
• Digital Transformation – Julien Pahud, Eli Lilly
• How to lead remotely – Susan Beckert, Merck
• HeForShe: what role can men play to achieve gender parity? - Dago Caceres, DuPont Nutrition & Biosciences
• Mentorship - Rina Chokshi, DuPont Nutrition & Biosciences

18:00-18:30 | Cocktail Reception & Networking

Add your pass to the Leadership Forum at registration – already registered? You can still add a pass to your existing registration!